Weining Lu, MD

The primary research interests in Dr. Lu’s laboratory focus on four scientific areas: 1. Molecular genetics of renal tract development and birth defects in the kidney and urinary tract; 2. Biological functions and disease mechanisms of renal tract birth defect genes and their roles after birth in common kidney disease; 3. SLIT-ROBO and ZEB signaling in kidney development and disease; 4. Discover and develop novel drug targets and therapeutics for patients with kidney disease.

Congenital anomalies of the kidney and urinary tract (CAKUT) is a complex birth defect with a diverse phenotypic spectrum, including kidney anomalies (e.g. renal agenesis, multicystic dysplastic kidney (MCDK), renal cystic disease, hydronephrosis), and ureteric anomalies (e.g. vesicoureteral reflux (VUR), reflux nephropathy, and obstructive uropathy) (Ref 1, 2). CAKUT is a genetically heterogeneous disorder with an incidence of 1 in 100 infants and accounts for up to 50-60% of the diagnoses underlying chronic kidney disease among the 0 to 12-year age group. CAKUT is also the leading cause of chronic kidney disease and renal failure in children and a major risk factor for kidney failure in adults (Ref 3). Despite high incidence of CAKUT in children and adults with chronic kidney disease and renal failure, the genetic and molecular bases of CAKUT remain largely unclear.

Dr. Lu’s translational research program has adopted combined human and mouse molecular genetics approaches to identify a number of developmental genes to the study of kidney and urinary tract development and pathogenesis of CAKUT and chronic kidney disease. The first human molecular genetics approach is to study individuals with CAKUT and apparent genetic defects, with the aim of using gene mutations, genomic imbalances and chromosomal rearrangements as signposts to identify these critical genes (reverse genetics) (Ref 2). Thereafter, molecular identification and analysis of candidate genes as well as mutation studies in affected individuals with a familial pattern of CAKUT will be carried out (forward genetics) (Ref 2, 4). The second approach is to study temporal and spatial expression patterns of candidate genes in human and mouse. Meanwhile, knockout and transgenic mouse models of candidate genes will be studied to elucidate more fully their roles in kidney and urinary tract development and disease (Ref 5-7). Once these candidate genes (e.g. SLIT2, ROBO2, ZEB2) have been identified, a multidisciplinary approach will be taken to gain further mechanistic insights in vivo and in vitro on the role of these genes in normal and abnormal developmental processes of the kidney and urinary tract, and on the pathogenesis of CAKUT and chronic kidney disease (Ref 5-7). This multidisciplinary approach includes the use of biomedical research technologies in human and mouse genetics, developmental biology, protein biochemistry, molecular biology, pathology, pharmacology, and drug target discovery. The goal is to provide new knowledge of disease mechanisms underlying developmental antecedents of kidney and urinary tract disorders, which will lead to discoveries of novel drug targets and therapeutics for patients with common kidney diseases (Ref 7) (https://www.eurekalert.org/pub_releases/2016-11/bumc-rip_1111516.php).

Current research activities in Dr. Lu’s lab include (1) Role of SLIT2-ROBO2 and ZEB2 signaling in renal tract development and disease, podocyte biology and injury, pericyte biology and renal fibrosis; (2) Discovery of novel causative and susceptibility genes (e.g. ROBO2, SLIT2, SRGAP1, ZEB2) for renal tract birth defects in children with chronic kidney disease; (3) Identify novel drug targets and therapeutics for patients with chronic kidney disease. Dr. Lu’s research program is supported by grants from the National Institutes of Health (NIH) and Pfizer Centers for Therapeutic Innovation.


(1). Lu W, Bush KT, Nigam SK. Regulation of ureteric bud outgrowth and the consequences of disrupted development. In Kidney Development, Disease, Repair and Regeneration (ed. Little MH), Pages 209-227 (Elsevier, 2016) (http://www.sciencedirect.com/science/article/pii/B9780128001028000187)
(2). Lu W, van Eerde AM, Fan X, et al. Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux. Am J Hum Genet 2007; 80:616-632. PMID: 17357069 (http://www.ncbi.nlm.nih.gov/pubmed/17357069).
(3) Calderon-Margalit R, Golan E, Twig G, et al. History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease. N Engl J Med 2018; 378(5):4280438. PMID: 29385364 (https://www.ncbi.nlm.nih.gov/pubmed/29385364).
(4) Hwang DY, Kohl S, Fan X, et al. Mutations of the SLIT2-ROBO2 pathway genes SLIT2 and SRGAP1 Confer Risk for Congenital Anomalies of the Kidney and Urinary Tract. Hum Genet 2015; 134(8):905-916; PMID: 26026792 (http://www.ncbi.nlm.nih.gov/pubmed/26026792).
(5). Fan X, Li Q, Pisarek-Horowitz A, et al. Inhibitory effects of Robo2 on nephrin: a crosstalk between positive and negative signals regulating podocyte structure. Cell Reports 2012; 2:52-61. PMID: 22840396 (http://www.ncbi.nlm.nih.gov/pubmed/22840396).
(6). Rasouly HM, Kumar S, Chen S, et al. Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic kidney disease. Kidney Int 2016; Aug 30. PMID: 27591083 (http://www.ncbi.nlm.nih.gov/pubmed/27591083).
(7) Fan X, Yang H, Kumar S, et al. SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. JCI Insight 2016, Nov 17; 1(19):e86934. PMID: 27882344 (https://www.ncbi.nlm.nih.gov/pubmed/27882344)

Vision Statement of Dr. Lu’s laboratory on science and education: (1) to advance new knowledge, biomedical innovation, and scientific learning; (2) to promote understanding, collaboration, diversity in biomedical research and education; (3) to contribute positively to scientific, medical and biomedical community, and society at large.
Core values: curiosity & innovation, diversity & collaboration, hard work & perseverance, honesty & fair play, courage & integrity.


Xueping Fan (PhD, McGill University), Instructor in Medicine, 617-414-1772, xpfan@bu.edu.

Sudhir Kumar (DVM, Ludwig Maximilians University Munich), Postdoc, 617-638-7353, kumars@bu.edu.

Richa Sharma (PhD, SGPGIMS Medical Institute in Lucknow), Postdoc, 617-414-2298, richa26@bu.edu.

Tou S. Thao (MS in Medical Sciences Program, Graduate Medical Sciences, Boston University School of Medicine), Graduate student, 617-414-2238, tthao@bu.edu


Hila Milo Rasouly (PhD, Graduate Program in Genetics and Genomics, Graduate Medical Sciences, Boston University School of Medicine). PhD thesis title: Discovery and analysis of genes important in kidney development and disease (https://open.bu.edu/handle/2144/13984).

Anna Pisarek-Horowitz (PhD, Graduate Program in Molecular Translational Medicine, Graduate Medical Sciences, Boston University School of Medicine). Functional characterization of the SLIT2-ROBO2 signaling pathway in the podocyte (https://open.bu.edu/handle/2144/13990).

Postdoc position and thesis project for graduate students are available. For inquiries regarding these positions, please contact Dr. Lu at wlu@bu.edu

Boston Medical Center

2018 American Society of Nephrology, USA: Fellow of American Society of Nephrology (FASN)
2007-2008 The National Kidney Foundation of MA/RI/NH/VT, USA: Pediatric Renal Research Award
2005-2007 National Kidney Foundation, USA: Young Investigator Grant
2005 Chinese American Society of Nephrology, USA: Young Investigator Award
1997 NIH-NIDDK Polycystic Kidney Disease Workshop, USA: Young Investigator Travel Award
1989 Zhejiang University School of Medicine: Excellent Medical Intern Award
1988 Zhejiang University School of Medicine: Excellent Medical Student Award
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. van der Ven AT, Connaughton DM, Ityel H, Mann N, Nakayama M, Chen J, Vivante A, Hwang DY, Schulz J, Braun DA, Schmidt JM, Schapiro D, Schneider R, Warejko JK, Daga A, Majmundar AJ, Tan W, Jobst-Schwan T, Hermle T, Widmeier E, Ashraf S, Amar A, Hoogstraaten CA, Hugo H, Kitzler TM, Kause F, Kolvenbach CM, Dai R, Spaneas L, Amann K, Stein DR, Baum MA, Somers MJG, Rodig NM, Ferguson MA, Traum AZ, Daouk GH, Bogdanovic R, Stajic N, Soliman NA, Kari JA, El Desoky S, Fathy HM, Milosevic D, Al-Saffar M, Awad HS, Eid LA, Selvin A, Senguttuvan P, Sanna-Cherchi S, Rehm HL, MacArthur DG, Lek M, Laricchia KM, Wilson MW, Mane SM, Lifton RP, Lee RS, Bauer SB, Lu W, Reutter HM, Tasic V, Shril S, Hildebrandt F. Whole-Exome Sequencing Identifies Causative Mutations in Families with Congenital Anomalies of the Kidney and Urinary Tract. J Am Soc Nephrol. 2018 Sep; 29(9):2348-2361. PMID: 30143558; DOI: 10.1681/ASN.2017121265;.
  2. van der Ven AT, Kobbe B, Kohl S, Shril S, Pogoda HM, Imhof T, Ityel H, Vivante A, Chen J, Hwang DY, Connaughton DM, Mann N, Widmeier E, Taglienti M, Schmidt JM, Nakayama M, Senguttuvan P, Kumar S, Tasic V, Kehinde EO, Mane SM, Lifton RP, Soliman N, Lu W, Bauer SB, Hammerschmidt M, Wagener R, Hildebrandt F. A homozygous missense variant in VWA2, encoding an interactor of the Fraser-complex, in a patient with vesicoureteral reflux. PLoS One. 2018; 13(1):e0191224. PMID: 29351342; DOI: 10.1371/journal.pone.0191224;.
  3. Tumelty KE, Higginson-Scott N, Fan X, Bajaj P, Knowlton KM, Shamashkin M, Coyle AJ, Lu W, Berasi SP. Identification of direct negative cross-talk between the SLIT2 and bone morphogenetic protein-Gremlin signaling pathways. J Biol Chem. 2018 03 02; 293(9):3039-3055.View Related Profiles. PMID: 29317497; DOI: 10.1074/jbc.M117.804021;.
  4. Gore BB, Miller SM, Jo YS, Baird MA, Hoon M, Sanford CA, Hunker A, Lu W, Wong RO, Zweifel LS. Roundabout receptor 2 maintains inhibitory control of the adult midbrain. Elife. 2017 04 10; 6. PMID: 28394253; DOI: 10.7554/eLife.23858;.
  5. Vivante A, Mann N, Yonath H, Weiss AC, Getwan M, Kaminski MM, Bohnenpoll T, Teyssier C, Chen J, Shril S, van der Ven AT, Ityel H, Schmidt JM, Widmeier E, Bauer SB, Sanna-Cherchi S, Gharavi AG, Lu W, Magen D, Shukrun R, Lifton RP, Tasic V, Stanescu HC, Cavaillès V, Kleta R, Anikster Y, Dekel B, Kispert A, Lienkamp SS, Hildebrandt F. A Dominant Mutation in Nuclear Receptor Interacting Protein 1 Causes Urinary Tract Malformations via Dysregulation of Retinoic Acid Signaling. J Am Soc Nephrol. 2017 Aug; 28(8):2364-2376. PMID: 28381549; DOI: 10.1681/ASN.2016060694;.
  6. Chen J, Van Der Ven A, Newman J, Vivante A, Mann N, Shril S, Schulz J, Ityel H, Schmidt MJ, Widmeier E, Gileadi O, Sharrocks A, Palmer K, Costantini K, Cebrian C, Thowfeequ S, Wenger RH, Bauer SB, Lee RS, Lu W, Lienkamp SS, Lifton RP, Tasic V, Kehinde EO, Hildebrandt F. ETV4 mutation in a patient with congenital anomalies of the kidney and urinary tract. International Journal of Pediatrics and Child Health. 2016; 2(4):61-71. View Publication
  7. Fan X, Yang H, Kumar S, Tumelty KE, Pisarek-Horowitz A, Rasouly HM, Sharma R, Chan S, Tyminski E, Shamashkin M, Belghasem M, Henderson JM, Coyle AJ, Salant DJ, Berasi SP, Lu W. SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. JCI Insight. 2016 11 17; 1(19):e86934.View Related Profiles. PMID: 27882344.
  8. Havasi A, Lu W, Cohen HT, Beck L, Wang Z, Igwebuike C, Borkan SC. Blocking peptides and molecular mimicry as treatment for kidney disease. Am J Physiol Renal Physiol. 2017 Jun 01; 312(6):F1016-F1025.View Related Profiles. PMID: 27654896; DOI: 10.1152/ajprenal.00601.2015;.
  9. Rasouly HM, Kumar S, Chan S, Pisarek-Horowitz A, Sharma R, Xi QJ, Nishizaki Y, Higashi Y, Salant DJ, Maas RL, Lu W. Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic disease. Kidney Int. 2016 Dec; 90(6):1262-1273.View Related Profiles. PMID: 27591083; DOI: 10.1016/j.kint.2016.06.037;.
  10. Lu W, Bush KT, Nigam SK. Regulation of Ureteric Bud Outgrowth and the Consequences of Disrupted Development. In "Kidney Development, Disease, Repair and Regeneration" (ed. Little MH). Academic Press. Elsevier. 2016; 209-227. View Publication
Showing 10 of 38 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 38 publications over 17 distinct years, with a maximum of 5 publications in 2016


Dr. Lu has completed the Boston University Medical Center CTSI Mentor Training Program.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map

Lu's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department